enGene reports interim data from LEGEND trial of detalimogene

enGene Therapeutics has reported additional interim outcomes from its ongoing LEGEND Phase II trial assessing detalimogene voraplasmid for BCG-unresponsive NMIBC. The trial enrolled 125 patients, with detalimogene achieving 54% CR any time and 43% at six months. NMIBC forms when cancer cells stay in the bladder lining, appearing as papillary growths or CIS lesions. Credit: Orawan Pattarawimonchai / Shutterstock.com. enGene Therapeutics has reported additional interim outcomes from the pivotal cohort of its ongoing LEGEND Phase II trial assessing detalimogene voraplasmid for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). The open-label, multi-cohort ongoing trial targets patients with high-risk BCG-unresponsive NMIBC…

Source: Clinical Trials Arena